NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax-L for Glioblastoma Brain Cancer

Source :: Legal Monitor Worldwide. June 4, 2020
Publication Year :: 2020
Abstract: Northwest Biotherapeutics, Inc. (OTCQB: NWBO)('NW Bio'), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of [...]

Subjects :: Northwest Biotherapeutics Inc. -- Product development
Coronaviruses
Brain cancer -- Care and treatment
Glioblastomas -- Care and treatment
Brain tumors
Gliomas
Data collection
Cancer
Immunotherapy
Tumors
Biotechnology industries
Business, international
Law

Tools